Etanercept-induced granulomatous hepatitis as a rare cause of abnormal liver tests

Acta Gastroenterol Belg. 2019 Jan-Mar;82(1):93-95.

Abstract

The authors report the case of a 76 year-old man with rheumatoid arthritis treated with prednisolone and etanercept. The patient was seen for persistent changes in liver tests lasting for six months, with a mixed pattern. The patient denied intake of new drugs or dietary/herbal supplements. Imaging studies showed mild steatosis. Additional study for chronic liver diseases only revealed positivity for anti-nuclear antibodies. Liver biopsy revealed noncaseating granulomas in some portal tracts. Consequent etiologic study for granulomatous diseases showed negative or normal results. So it was decided to suspend etanercept, with a subsequent gradual improvement on analytical parameters that normalized three months later. To date, only one case of granulomatous liver disease associated with an anti-TNF agent was described in the literature. This case also raises the question whether the development of granulomatous processes associated with anti-TNF agents has been underdiagnosed due to the presence of other concomitant immunosuppressant therapies.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Chemical and Drug Induced Liver Injury*
  • Etanercept / adverse effects*
  • Etanercept / therapeutic use
  • Granuloma / chemically induced*
  • Hepatitis / complications*
  • Humans
  • Immunoglobulin G
  • Liver Diseases
  • Male
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept